This MedLibrary.org supplementary page on Budesonide is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
|
Budesonide
|
|
| Systematic (IUPAC) name | |
| 16,17-(butylidenebis(oxy))-11,21-dihydroxy-, (11-β,16-α)-pregna-1,4-diene-3,20-dione | |
| Identifiers | |
| CAS number | |
| ATC code | A07 D07, R01, R03 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C25H34O6 |
| Mol. mass | 430.534 g/mol |
| SMILES | & |
| Pharmacokinetic data | |
| Bioavailability | 100% (but large first pass effect) |
| Protein binding | 85-90% |
| Metabolism | Hepatic CYP3A4 |
| Half life | 2.0-3.6 hours |
| Excretion | Renal, Faecal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral, Nasal, tracheal, rectal |
Budesonide is a glucocorticoid steroid for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis. Additionally, it is used for inflammatory bowel disease. It is marketed by AstraZeneca as a nasal inhalation with the brand name Rhinocort (in Denmark, as Rhinosol), as an oral inhalation with the brand name Pulmicort, and as an enema and a modified-release capsule with the brand name Entocort. It is also sold in combination with formoterol (Oxis) in a single inhaler, with the brand name Symbicort.
Contents |
Pharmacology
Budesonide has a high first pass metabolism. It has efficacy in the terminal ileum and the right colon. Budesonide in comparison with prednisolone has been associated with fewer bone density losses and unlike other corticosteroids has little influence on the hypothalamic-pituitary-adrenal axis which also limit the need of tapering before discontinuation. Overall, it has a lower incidence of systemic manifestations than similar medications.
Side Effects
Budesonide may cause[1]:
- nose irritation or burning
- bleeding or sores in the nose
- lightheadedness
- upset stomach
- cough
- hoarseness
- dry mouth
- rash
- sore throat
- bad taste in mouth
- change in mucus color
In addition the following should be reported:
- Immediately if difficulty breathing or swelling of the face
- white patches in the throat, mouth, or nose
- irregular menstrual periods
- severe acne
- rarely, behavioral changes—when these do occur, they seem to mostly affect children. For citation, see reference above.
Recall
Pulmicort inhalers were recalled in 2002 because there was concern that they may not always have provided the full dosage.
References
External links
|
||||||||||||||||||||
|
|||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
Wikipedia content modification information:
- This page was last modified on 23 September 2008, at 16:48.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Budesonide".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.